Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Balaxi Pharmaceuticals Ltd (BALAXI) is currently trading at 18.13 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Balaxi Pharmaceuticals Limited is a branded, IPR-driven pharmaceutical company focused on OTC and branded generics in frontier markets across Latin America and Africa, operating an asset-light distribution network of 38 warehouses and owned fleet while sourcing finished products from WHO‑GMP contract manufacturers across India, China and Portugal and selling through its local subsidiaries. In Q3 FY26 Balaxi completed commissioning, qualification and validation of its first in-house formulation facility at Jadcherla for general oral solid dosages, marking a deliberate move from 'asset-light' to 'asset-right' and enabling backward integration, faster regulatory approvals, improved quality control and expected margin enhancement as the plant begins commercial supply to LATAM and African markets. Q3 FY26 revenue was ₹72.54 crore, down 1% YoY but up 29% QoQ, while gross profit remained healthy with gross margin above 42%; however EBITDA and PAT contracted materially due to elevated operating costs and an extended working capital cycle in Angola, signalling near-term margin pressure as the company pivots toward institutional and hospital channels. Balaxi’s differentiated strategy targets top‑2 positions in selected semi‑regulated frontier markets by leveraging deep local distribution, 100+ Indian expatriates embedded in operations, digitized regulatory affairs, and a product registration pipeline of 948 registrations with 200+ pending, supporting rapid new product introductions across prioritized Latin American and African geographies. The firm completed a preferential fundraising in FY20‑25 and is now pursuing geographic expansion into Ecuador and Chile, while maintaining product mix concentration in antibiotics and essential OTC categories; digital procurement, regulatory management and CRM initiatives aim to standardize processes and scale the produce‑stock‑sell model to new frontier markets.
Over the past 52 weeks, Balaxi Pharmaceuticals Ltd has traded between a low of ₹18.00 and a high of ₹76.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Balaxi Pharmaceuticals Ltd has a market capitalization of approximately 104.23. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Balaxi Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 10.60 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 104.23 Cr, Balaxi Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Balaxi Pharmaceuticals Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Balaxi Pharmaceuticals Ltd is 10.60. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
5.38 | 124 Cr | 269.00 | 3.92 | 0.00 | 1.74 | 2.24 | 0.00 | |
111.00 | 123 Cr | 26.37 | 2.30 | 0.00 | 15.37 | 16.39 | 8.19 | |
74.86 | 119 Cr | 14.68 | 1.52 | 1.60 | 8.71 | 8.78 | 2.33 | |
18.88 | 104 Cr | 11.04 | 0.44 | 0.00 | 6.09 | 7.48 | 2.93 | |
72.00 | 100 Cr | 11.46 | 1.14 | 2.08 | 8.16 | 14.50 | 7.05 | |
6.79 | 89 Cr | -2.40 | 1.31 | 0.00 | -0.57 | 1.54 | -0.43 | |
99.95 | 81 Cr | 9.71 | 2.16 | 0.00 | 0.00 | 0.00 | 0.00 |
Bearish
4
Neutral
2
Bullish
8
Bearish
36
Neutral
2
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Balaxi Pharmaceuticals Limited is a branded, IPR-driven pharmaceutical company focused on OTC and branded generics in frontier markets across Latin America and Africa, operating an asset-light distribution network of 38 warehouses and owned fleet while sourcing finished products from WHO‑GMP contract manufacturers across India, China and Portugal and selling through its local subsidiaries.
In Q3 FY26 Balaxi completed commissioning, qualification and validation of its first in-house formulation facility at Jadcherla for general oral solid dosages, marking a deliberate move from 'asset-light' to 'asset-right' and enabling backward integration, faster regulatory approvals, improved quality control and expected margin enhancement as the plant begins commercial supply to LATAM and African markets.
Q3 FY26 revenue was ₹72.54 crore, down 1% YoY but up 29% QoQ, while gross profit remained healthy with gross margin above 42%; however EBITDA and PAT contracted materially due to elevated operating costs and an extended working capital cycle in Angola, signalling near-term margin pressure as the company pivots toward institutional and hospital channels.
Balaxi’s differentiated strategy targets top‑2 positions in selected semi‑regulated frontier markets by leveraging deep local distribution, 100+ Indian expatriates embedded in operations, digitized regulatory affairs, and a product registration pipeline of 948 registrations with 200+ pending, supporting rapid new product introductions across prioritized Latin American and African geographies.
The firm completed a preferential fundraising in FY20‑25 and is now pursuing geographic expansion into Ecuador and Chile, while maintaining product mix concentration in antibiotics and essential OTC categories; digital procurement, regulatory management and CRM initiatives aim to standardize processes and scale the produce‑stock‑sell model to new frontier markets.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
104 Cr
Low Risk
10.6
28.4
0.0
0.4
76.10
18.00
Sales CAGR
Profit CAGR
ROE
ROCE
